Skip Navigation
Johns Hopkins Bloomberg School of Public HealthCAAT

Publications -- Thomas Hartung, MD, PhD

Selected Publications:

2011
1. Dehus O, Pfitzenmaier M, Stuebs G, Fischer N, Schwaeble W, Morath S, Hartung T, Geyer A and Hermann C. Growth temperature-dependent expression of structural variants of Listeria monocytogenes lipoteichoic acid. Immunobiol 2011, 216:24-31. (IF 2.9)
2. Hartung T. From alternative methods to a new toxicology. Eur. J. Pharmaceutics Biopharmaceutics, 2011, in press. (IF 3.2)
3. Hartung T and Sabbioni E. Alternative in vitro assays in nanomaterial toxicology. WIREs Nanomed Nanobiotechnol 2010, in press

2010
1. Ball-Price AK, Hogberg HT, Buzanska L, Lenas P, van Vliet E and Hartung T. In vitro developmental neurotoxicity (DNT) testing: Relevant models and endpoints. Neurotox. 2010, 31:545-554. (IF 3.0)
2. Basketter DA, Kimber I and Hartung T. The evolution of validation: a commentary. Cutaneous Ocular Toxicol. 2010, 29:1-3. (IF 0.4)
3. Borisova M, Schleicher R, Schutt J, Góra A, Hartung T and von Aulock S. Conditioned supernatant from lipopolysaccharide stimulated blood mononuclear cells induces EMT in A549 cells: role of IL-1β and TNF-α. Submitted.
4. Borisova M, Góra A, Brylka E, Hartung T and von Aulock S. Lung epithelial cells constitutively produce an immunomodulatory factor for cytokine release by mononuclear cells. Submitted.
5. Bottini AA and Hartung T. The economics of animal testing. ALTEX Special Issue 2010, 27:67-77. (IF 1.3)
6. Bunk S, Sigel S, Metzdorf D, Sharif O, Triantafilou K, Triantafilou M, Hartung T, Knapp S and von Aulock S. Internalization and co-receptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J. Immunol., 185:3708-3717. (IF 6.1)
7. Daneshian M, Leist M, Hartung T. Center for alternatives to animal testing – Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology. ALTEX 2010, 27:63-69. (IF 1.3)
8. Daneshian M, Leist M, Hartung T. Das Center for Alternatives to Animal Testing – Europe (CAAT-EU): eine transatlantische Brücke für den Paradigmenwechsel in der Toxikologie. ALTEXethik 2010, 2, 90. (IF 1.3)
9. Daneshian M, Mertens M, Mayer C, Gabrio T, Hartung T and von Aulock S. Uniform cytokine induction by spores of different fungal species is not mediated by surface glycans. Med. Mycology, submitted.
10. Di Mauro C, Bouchon S, Logtmeijer C, Nordvik JP, Pride R and Hartung T. Structured approach to identifying European critical infrastructures. Int. J. Critical Infrastructures, 2010, 6:277-292.
11. Forti E, Bulgheroni A, Cetin Y, Hartung T, Jennings P, Pfaller W and Prieto P. Characterisation of cadmium chloride induced molecular and functional alterations in bronchial epithelial cells. Cell Physiol Biochem 2010, 25:159-168. (IF 3.6)
12. Hartung T. Comparative analysis of the revised Directive 2010/63/EU for the protection of laboratory animals with its predecessor 86/609/EEC – a t4 report. ALTEX 2010, 27:285-303. (IF 1.3)
13. Hartung T. Evidence based-toxicology – the toolbox of validation for the 21st century? ALTEX 2010, 27:241-251. (IF 1.3)
14. Hartung T. Lessons learned from alternative methods and their validation for a new toxicology in the 21st century. J. Toxicol. Env. Health 2010, 13:277-290. (IF 1.8)
15. Hartung, T. Food for thought… on alternative methods for chemical safety testing. ALTEX 2010, 27, 3-14. (IF 1.3)
16. Hartung, T. Food for thought… on alternative methods for nanoparticle safety testing. ALTEX 2010, 27, 87-95. (IF 1.3)
17. Hartung, T, Bruner L, Curren R, Eskes C, Goldberg A, McNamee P, Scott L and Zuang V. First alternative method validated by a retrospective weight-of-evidence approach to replace the Draize eye test for the identification of non-irritant substances for a defined applicability domain. ALTEX 2010, 27, 43-51. (IF 1.3)
18. Hartung T and Koeter H. Congress Chairmen´s Preface. ALTEX Special Issue 2010, 1-2. (IF 1.3)
19. Hartung, T. Vor- und Nachdenkliches… zu Alternativmethoden für die Sicherheitsprüfung von Chemikalien. ALTEXethik 2010, 2, 87. (IF 1.3)
20. Hartung, T, Bruner L, Curren R, Eskes C, Goldberg A, McNamee P, Scott L and Zuang V. Erste Alternativmethode zum Ersatz des Draize Augentests zur Identifizierung nicht-irritativer Substanzen für eine definierte Applikationsdomäne durch einen retrospektiven weight-of-evidence-Ansatz validiert. ALTEX 2010, ALTEXethik 2010, 2, 89. (IF 1.3)
21. Hartung, T. Vor- und Nachdenkliches… zu Alternativmethoden für die Sicherheitsprüfung von Nanopartikeln. ALTEXethik 2010, 2, 91. (IF 1.3)
22. Hartung T. Evidenz-basierte Toxikologie – die richtige Methodensammlung für Validierung im 21. Jahrhundert? ALTEXethik 2010, 2, 102. (IF 1.3)
23. Hartung T. Vergleichende Analyse der überarbeiteten Richtlinie 2010/63/EU für den Schutz von Labortieren mit der abgelösten Richtlinie 86/609/EEC – ein t4 Bericht. ALTEXethik 2010, 2, 103. (IF 1.3)
24. Hogberg HT, Kinsner-Ovaskainen A, Coecke S, Hartung T and Bal-Price AK. mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach. Tox. Sci. 2010, 113:95-115. (IF 3.8)
25. Presgrave O, Eskes C, Presgrave R, Alves E, Freitas JC, Caldeira C, Gimines I, Silva R, Nogueira S, Nunes J, Rivera E, Sá-Rocha V, Coecke S and Hartung T. A Proposal to Establish a Brazilian Center for Validation of Alternative Methods (BraCVAM). ALTEX Special Issue 2010, 27:159-161. (IF 1.3)
26. Rockel C, Hartung T and Hermann C. Different S. aureus whole bacteria mutated in putative pro-inflammatory membrane components have similar cytokine-inducing activity, Immunobiol 2010, in press. (IF 2.9)
27. Rockel C, Sigel S, Borisova M, Deininger S, Draing C, Dehus O, Pfitzenmeier M, Geyer A, Götz F, Hartung T, Bunk S, Hermann C and von Aulock S. Lipoteichoic acids from a Staphylococcus aureus wildtype strain and a lipoprotein diacylglycerol transferase deletion mutant possess similar immune stimulatory activity in human monocytes but not in cell lines, submitted.
28. Scott L, Eskes C, Hoffmann S, Adriaens E, Alepée N, Bufo M, Clothier R, Facchini D, Faller C, Guest R, Harbell J, Hartung T, Kamp H, Le Varlet B; Meloni M, McNamee P, Osborne R, Pape W, Pfannenbecker U, Prinsen M, Seaman C, Spielmann H, Stokes W, Trouba K, Van den Berghe C, van Goethem F, Vassallo M, Vinardell P and Zuang V. A proposed eye irritation testing strategy to reduce and replace in vivo studies using bottom-up and top-down approaches. Toxicol. In Vitro 2009, 24:1-9. (IF 2.2)
29. Sigel S, Bunk S, Herrmann V, Draing C, Hartung T and von Aulock S. Peptidoglycan directly and indirectly contributes to Staphylococcus aureus-mediated IFNg release in human whole blood, submitted

2009
1. Bottini AA and Hartung T. Food for thought… on economics of animal testing. ALTEX 2009, 26:3-16. (IF 1.3)
2. Bottini AA and Hartung T. Vor- und Nachdenkliches… zu ökonmischen Aspekten von Tierversuchen. ALTEX ethik 2009, 1:94-99.
3. Bulgheroni A, Kinsner-Ovaskainen A, Hoffmann S, Hartung T and Prieto P. Estimation of acute oral toxicity using no adverse effect level (NOAEL) from the 28-day repeated dose toxicity studies in rats. Reg. Tox. Pharmacol. 2009, 53:16-19. (IF 2.0)
4. Corvi R and Hartung T. Alternative in vitro methods for carcinogenicity and mutagenicity. Exp. Toxicol. Pathol. 2009, 61:255. (IF 1.3)
5. Daneshian M, von Aulock S and Hartung T. Assessment of pyrogenic contaminations with the validated human whole blood assay. Nature Protocols 2009, 12:1709-1721. (IF 1.7)
6. Eskes C, de Moura Sa-Rocha V, Nunes J, Presgrave O, de Carvalho D, Masson P, Rivera E, Coecke S, Kreysa J and Hartung T. Proposal for a Brazilian centre on alternative test methods. ALTEX 2009, 26:265-268. (IF 1.3)
7. Ferrario D, Collotta A, Carfi M, Bowe G, Vahter M, Hartung T and Gribaldo L. Arsenic induces telomerase expression and maintains telomere length in human cord blood cells. Toxicology 2009, 260:132-141. (IF 2.9)
8. Griesinger C, Hoffmann S, Kinsner-Ovaskainen A, Coecke S and Hartung T. Proceedings of the First International Forum Towards Evidence-Based Toxicology. Conference Centre Spazio Villa Erba, Como, Italy. 15−18 October 2007. Preface. Human Exp Toxicol 2008, Special Issue: Evidence-Based Toxicology (EBT) 2009, 28:83-86. (IF 1.3)
9. Griesinger C, Hoffmann S, Kinsner A, Coecke S and Hartung T. Current schemes for decision-making in toxicology. Human Exp Toxicol 2009, 28:147. (IF 1.3)
10. Griesinger C, Hoffmann S, Kinsner A, Coecke S and Hartung T. Current information sources for hazard identification. Human Exp Toxicol 2009, 28:149. (IF 1.3)
11. Griesinger C, Hoffmann S, Kinsner A, Coecke S and Hartung T. Evidence-based tools in toxicological basic research. Human Exp Toxicol 2009, 28:151-152. (IF 1.3)
12. Griesinger C, Hoffmann S, Kinsner A, Coecke S and Hartung T. Evidence-based tools in toxicological hazard identification. Human Exp Toxicol 2009, 28:153. (IF 1.3)
13. Griesinger C, Hoffmann S, Kinsner A, Coecke S and Hartung T. Evidence-based tools in toxicological decision-making. Human Exp Toxicol 2009, 28:155. (IF 1.3)
14. Griesinger C, Hoffmann S, Kinsner A, Coecke S and Hartung T. Possible improvement of information sources on hazard and risk. Human Exp Toxicol 2009, 28:157. (IF 1.3)
15. Hartung T, Blaauboer B and Leist M. Food for thought… on education in alternative methods in toxicology. ALTEX 2009, 26:255-263. (IF 1.3)
16. Hartung T and Rovida C. Chemical regulators have overreached. Nature 2009, 460:1080-1081. (IF 28.8)
17. Hartung T. Toxicology for the twenty-first century. Nature 2009, 460:208-212. (IF 28.8)
18. Hartung T. Fundamentals of an evidence-based toxicology Human Exp Toxicol 2009, 28:93-94. (IF 1.3)
19. Hartung T. A toxicology for the 21st century: Mapping the road ahead. Tox. Sci. 2009, 109:18-23. (IF 3.8)
20. Hartung T. Food for thought… on evidence-based toxicology. ALTEX 2009, 26:75-82. (IF 1.3)
21. Hartung T. Per aspirin ad astra... ATLA - Altern Lab Anim 2009, 37, Suppl 2:45-47. (IF 3.2)
22. Hartung T and Daston G. Are in vitro tests suitable for regulatory use? Tox. Sci. 2009, in 111:233-237. (IF 3.8)
23. Hartung T and Hoffmann S. Food for thought on…. in silico methods in toxicology. ALTEX 2009, 26:155-166. (IF 1.3)
24. Hartung T. Vor- und Nachdenkliches… zu Evidenz-basierten Toxikologie. ALTEX ethik 2009, 1:102-106.
25. Hartung T and Hoffmann S. Vor- und Nachdenkliches… zu in silico Methoden in der Toxikologie. ALTEX ethik 2009, 1:108-109.
26. Hartung T, Blaauboer B and Leist M. Vor- und Nachdenkliches… zur Lehre von Alternativmethoden in der Toxikologie. ALTEX ethik 2009, 1:117-120.
27. Hogberg H, Kinsner A, Hartung T, Coecke S and Bal-Price A. Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides. Toxicol. Appl. Pharmacol. 2009, 235:268-286. (IF 3.9)
28. Kinsner-Ovaskainen A; Griesinger C, Hoffmann A, Coecke S, Bowe G, Campana C and Hartung T. An online portal to evidence-based toxicology. Human Exp Toxicol 2009, 28:161-162. (IF 1.3)
29. Kinsner-Ovaskainen A, Bulgheroni A, Hartung T and Prieto P. ECVAM’s ongoing activities in the area of acute oral toxicity. Toxicol. In vitro 2009, in press. (IF 2.2)
30. Moore N, Bremer S, Carmichael N, Daston G, Dent M, Gaoua-Chapelle W, Hallmark N, Hartung T, Holzum B, Hübel U, Meisters M-L, Schneider S, van Ravenzwaay B and Hennes C. A modular approach to the extended one-generation reproduction toxicity study: Outcome of an ECETOC task force and International ECETOC/ECVAM workshop. ATLA – Altern. Lab. Anim. 2009, 37:219-225. (IF 3.2)
31. Rahman O, Pfitzenmaier M, Pester O, Morath S, Cummings SP, Hartung T and Sutcliffe IC. Macroamphiphilic components of thermophilic actinomycetes: identification of lipoteichoic acid in Thermobifida fusca. J. Bacteriol. 2008, 191:152-160. (IF 4.0)
32. Rovida C. and Hartung T. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements. ALTEX 2009, 26:187-208. (IF 1.3)
33. Rovida C. and Hartung T. Neuevaluierung der erforderlichen Tierzahlen und Kosten der in vivo Tests zur Erfüllung der REACH Vorgaben für Chemikalien – ein Bericht des “transatlantic think tank for toxicology (t4)”. ALTEX ethik 2009, 1:115.
34. Schindler S, von Aulock S, Daneshian M and Hartung T. Development, validation and applications of the monocyte activation test for pyrogens based on human whole blood. ALTEX 2009, 26:293-305. (IF 1.3)
35. Schindler S, von Aulock S, Daneshian M and Hartung T. Entwicklung, Validierung und Anwendungsbereiche des Monozyten Aktivationstests für Pyrogene auf der Basis menschlichen Vollbluts. ALTEX ethik 2009, 1:122.
36. Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler L, Kinsner-Ovaskainen A, Hartung T and Hoffmann S. "ToxRTool", a new tool to assess the reliability of toxicological data. Toxicol. Lett. 2009, 189:138-144. (IF 3.3)
Schwarz M, Bremer S, Dencker L, Garthoff B, Hartung T, Lazzari G, Mantovani A, Pellizzer C and Spielmann H. ReProTect: Hazard assessment of reproductive toxicity. Toxicol. Lett. 2009, 189, Suppl. 1:S37. (IF 3.3)